Skip to main content

Table 1 Patient characteristics.

From: PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma

Variables Total PD-L1 (−) PD-L1 (+) P value
   54 (80.6%) 13 (19.4%)  
Age (Median) 48 51 (38–73) 45 (22–72)  
Sex 0.82
 Male 38 31 (81.6%) 7 (18.4%)  
 Female 29 23 (79.3%) 6 (20.7%)  
ECOG 0.99
 0 3 3 (100%) 0 (0.0%)  
 1 36 28 (77.8%) 8 (22.2%)  
 2 26 21 (80.8%) 5 (19.2%)  
 Not available 2 2 (100%) 0 (0.0%)  
Histologic variant 0.22
 Leiomyosarcoma 18 15 (83.3%) 3 (16.7%)  
 Undifferentiated pleomorphic sarcoma 13 9 (69.2%) 4 (30.8%)  
 Angiosarcoma 8 5 (62.5%) 3 (37.5%)  
 Synovial sarcoma 6 6 (100%) 0 (0.0%)  
 Myofibroblastic sarcoma 6 5 (83.3%) 1 (16.7%)  
 MPNST 5 3 (60%) 2 (40%)  
 Etc* 11 11 (100%) 0 (0.0%)  
Primary site 0.23
 Abdomen/pelvis 23 20 (87.0%) 3 (13.0%)  
 Extremity 22 19 (86.4%) 3 (13.6%)  
 Thorax 18 13 (72.2%) 5 (27.8%)  
 Head/neck 4 2 (50%) 2 (50%)  
FNCLCC grade 0.36
 I 6 6 (100%) 0 (0.0%)  
 II 33 27 (81.8%) 6 (19.2%)  
 III 28 21 (75%) 7 (25%)  
Number of previous chemotherapy 0.83
 1 48 38 (79.2%) 10 (20.8%)  
 2 18 15 (83.3%) 3 (16.7%)  
 3 1 1 (100%) 0 (0.0%)  
Type of previous chemotherapy received NA
 Doxorubicin monotherapy 9 7 (77.8%) 2 (22.2%)  
Ifosfamide monotherapy 3 2 (66.7%) 1 (33.3%)  
 Paclitaxel 4 3 (75.0%) 1 (25.0%)  
 Doxorubicin combination 33 28 (84.8%) 5 (15.2%)  
 Ifosfamide combination 4 3 (66.7%) 1 (33.3%)  
 Cyclophosphamide based 14 11 (78.6%) 3 (21.4%)  
 Gemcitabine/docetaxel 14 12 (85.7%) 2 (14.3%)  
  1. * 8th edition of the American Joint Committee on Cancer guideline of tumor, node, and metastasis (TNM) classification
  2. *Etc: ASPS (alveolar soft part sarcoma, n = 3), epithelioid sarcoma (n = 3), DSRCT (desmoplastic small round cell tumors, n = 1), osteosarcoma (n = 1), liposarcoma (n = 1), rhabdomyosarcoma (n = 1), and PECOMA (perivascular epithelioid cell tumors, n = 1)
  3. Abbreviation: Eastern Cooperative Oncology Group (ECOG), malignant peripheral nerve sheath tumor (MPNST), Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC)
\